Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
27 Evidence From Clinical Trials The clinical evidence supporting the use of GLP-1RAs in HF has primarily emerged from cardiovascular outcome trials (CVOTs) in patients with T2D and dedicated HF trials ( Table 1 )
However, it is important to avoid excessive intake of overlapping vitamins
N Engl J Med, 2021
The main outcome was hospitalization for heart failure and other outcomes were MACE outcomes (cardiovascular mortality, myocardial infarction, stroke, and all-cause mortality), metabolic outcomes (changes in HbA 1 c, weight, fasting plasma glucose (FPG)), and safety outcomes (severe adverse events, nausea, diarrhea, severe hypoglycemia, urinary tract infection, adverse events-related discontinuation)
US$ 28.93
US$ 22.55
US$ 27.91
US$ 26.40
